FDA Upgrades Recall on 160,000+ Bottles of Thyroid Medication

Key Takeaways

• The U.S. Food and Drug Administration has updated its recall of a common thyroid medication to Class II

• The recall is due to subpotent active ingredients

• It affects roughly 160,630 bottles of levothyroxine sodium tablets